Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.88 |
| ▸ | NOS1 | P29475 | 7/20 | 0.58 |
| ▸ | NOS3 | P29474 | 4/20 | 0.58 |
| ▸ | NOS2 | P35228 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimaprit SCHEMBL7174665 | 0.98 | HRH4 (0.96) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| Dimaprit SCHEMBL30836911 | 0.98 | HRH4 (0.96) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| Dimaprit SCHEMBL7173650 | 0.98 | HRH4 (1.00) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| SCHEMBL12648461 | 0.93 | HSD17B10 (1.00) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| Hydrochloric Acid SCHEMBL7367775 | 0.91 | ALDH1A1 (1.00) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| SCHEMBL7216548 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL3588464 | 0.84 | ALDH1A1 (0.73) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| Hydrochloric Acid SCHEMBL7176136 | 0.79 | HRH4 (0.66) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| Bromide SCHEMBL7180345 | 0.79 | HRH4 (0.69) | HRH4CYP1A2TDP1ALDH1A1HRH2 | |
| SCHEMBL11597746 | 0.78 | CYP1A2 (0.64) | HRH4CYP1A2TDP1ALDH1A1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251478-B2 | Bioactive polymeric dressing for accelerated wound closure | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2025-03-18 | — | — | US | claimed |
| US-20240261459-A1 | BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | claimed |
| US-11896724-B2 | Bioactive polymeric dressing for accelerated wound closure | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-02-13 | — | — | US | claimed |
| US-20210100927-A1 | BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2021-04-08 | — | — | US | claimed |
| EP-2841566-B1 | DERIVATION OF NEURAL STEM CELLS AND DOPAMINERGIC NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | INT STEM CELL CORPORATION (US) | 2019-03-13 | — | — | EP | claimed |
| US-20140107124-A1 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES | ALLERGAN, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20100143322-A1 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT PATENT & LICENCE TRADING LTD., C/O THE B-NET (GB) | 2010-06-10 | — | — | US | claimed |
| US-20090156581-A1 | Aminergic pharmaceutical compositions and methods | BOARD OF TRUSTREES OF MICHIGAN STATE UNIVERSITY (US) | 2009-06-18 | — | — | US | claimed |
| EP-1917006-A2 | USE OF INHIBITORS OF N-METHYL TRANSFERASES FOR THE THERAPY OF PARKINSON'S DISEASE | PLT Patent & Licence Trading Ltd. (GB) | 2008-05-07 | — | — | EP | claimed |
| US-20080039507-A1 | Novel Prostamides For The Treatment Of Glaucoma And Related Diseases | ALLERGAN, INC. | 2008-02-14 | — | — | US | claimed |
| US-5952361-A | Compositions | DIAS NAHOUM CESAR ROBERTO (US) | 1999-09-14 | — | — | US | claimed |
| US-5908853-A | THERAPY FOR SEXUAL DISORDERS | Nahoum, Cesar Roberto Dias (BR) | 1999-06-01 | — | — | US | claimed |
| WO-1999020265-A1 | COMPOSITIONS CONTAINING HISTAMINE H2 AGONISTS AND METHODS OF USE IN TREATING DRY EYE | ALCON LABORATORIES, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| EP-0655914-A4 | NOVEL COMPOSITIONS. | NAHOUM CESAR ROBERTO DIAS (BR) | 1998-04-22 | — | — | EP | claimed |
| US-5728378-A | ANTITUMOR AND ANTIVIRUS AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 1998-03-17 | — | — | US | claimed |
| EP-0655914-A1 | NOVEL COMPOSITIONS | NAHOUM, Cesar Roberto Dias (BR) | 1995-06-07 | — | — | EP | claimed |
| EP-0652768-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-ALPHA AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | MAXIM PHARMACEUTICALS, INC. (US) | 1995-05-17 | — | — | EP | claimed |
| WO-1994004120-A2 | METHODS OF TREATING SEXUAL DYSFUNCTION IN ANIMALS WITH AND H AGONIST | NAHOUM CESAR ROBERTO DIAS (BR) | 1994-03-03 | — | — | WO | claimed |
| WO-1993024144-A1 | PREPARATION FOR ACTIVATION OF NATURAL KILLER CELLS (NK-CELLS), SAID PREPARATION CONTAINING INTERFERON-α AND HISTAMINE, SEROTONIN OR SUBSTANCES WITH CORRESPONDING RECEPTOR ACTIVITY | SYNTELLO INC. (US) | 1993-12-09 | — | — | WO | claimed |
| US-4474876-A | Flow cytometric analysis of histamine receptors | TRUSTEES OF BOSTON UNIVERSITY (US) | 1984-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107124-A1 | NOVEL PROSTAMIDES FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES | PTGIS, PTGIR, PTGS1 | HRH4 613/4885CYP1A2 1157/4885TDP1 1517/4885 |
| US-20080039507-A1 | Novel Prostamides For The Treatment Of Glaucoma And Related Diseases | PTGIS, PTGIR, PTGS1 | HRH4 613/4885CYP1A2 1157/4885TDP1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.